Salesforce.com Inc. (CRM, Financial), Synchrony Financial (SYF, Financial), American Airlines Group Inc. (AAL, Financial) and Biogen Inc. (BIIB, Financial) were the largest insider buys for the week of May 5.
Salesforce.com director bought 1,154 shares
Director Susan Wojcicki bought 1,154 shares of Salesforce.com stock for $86.64 per share on May 1. The stock price has increased by 0.38% since.
Salesforce.com is an American-based company headquartered in San Francisco that specializes in cloud computing. Most of its revenue comes from customer relationship management products. However, Salesforce also utilizes commercial applications of social networking through acquisition to gain additional revenue. The company has a market cap of $61.58 billion, and as of May 5 it traded at $86.97 per share.
On March 6 Salesforce.com announced a global strategic partnership with IBM to deliver joint solutions designed to leverage artificial intelligence to enable companies to make smarter and faster decisions. The partnership promises to seamlessly connect the platforms and services of the two companies to provide a new level of intelligent customer engagement across services such as sales, service and marketing.
Synchrony Financial director bought 18,000 shares
Director Will W. Graylin bought 18,000 shares of Synchrony Financial stock for $27.8 per share on May 1. The stock price has increased by 2.91% since.
Synchrony Financial is an American financial services provider. The company offers consumer financing products such as credit, promotional financing, loyalty programs and installment lending. The company is the largest provider of private label credit cards in the U.S. The company has a market cap of $22.49 billion; as of May 5 it traded at $28.61.
On April 28 Synchrony Financial announced first-quarter 2017 net earnings of $499 million or 61 cents per diluted share. The net interest income increased 12% from the first quarter of 2016 to $3.6 billion. Loan receivables for the company grew $8 billion, or 11%, from the first quarter of 2016 to $73 billion, and the purchase volume increased 7% from the first quarter of 2016.
American Airlines Group director bought 3,000 shares
Director James F. Albaugh bought 3,000 shares of American Airlines Group stock on May 4 for $43.85. The stock price has increased by 1.51% since.
American Airlines Group is a major American airline holding company. The company is the largest airline in the world in terms of fleet size and revenue with 6,700 daily flights to 336 locations in 56 countries. As of 2016, the company’s assets were $51.274 billion. The company has a market cap of $21.28 billion, and as of May 5 it traded at $44.51.
On May 5, American Airlines Group launched new daily seasonal nonstop flights between Dallas-Fort Worth International Airport and Rome Fiumicino Airport and Amsterdam Airport Schiphol and between Chicago O’Hare International Airport and Barcelona-El Prat Airport. The new flights will run through Sept. 30.
Biogen director bought 73,858 shares
Director Alexander J. Denner bought 73,858 shares of Biogen stock on April 27 for $278.5 per share. The stock price has decreased by 5.87% since.
Biogen is an American international biotechnology company specializing in the research, development and delivery of therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases. Some of the company's products include Alprolix, Avonex, Eloctate, Fampyra and Gazyva. The company has a market cap of $56.15 billion. As of May 5 it traded at $262.15.
On April 25 Biogen announced its first quarter 2017 financial results. The company reported a total revenue of $2.8 billion, a 3% increase versus first-quarter 2016 and an 8% increase excluding hemophilia revenues. GAAP net income and diluted earnings per share were $748 million and $3.46.
For the complete list of stocks that were bought by their company executives, go to: Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Start a free seven-day trial of Premium Membership to GuruFocus.
